Patent Term Extension Application for ENSACOVE™ (ensartinib), Patent No. 9,126,947 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0493

Patent Term Extension Application for ENSACOVE™ (ensartinib), Patent No. 9,126,947

Documents

Comments

Description

Open

Comment Period OpensFeb 28, 2025

Comment Period ClosesMay 6, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; ENSACOVE FR Doc: 2026-04491	Mar 6, 2026	--

CDER

Patent Term Extension Application

Patent No. 9,126,947

ENSACOVE™ (ensartinib)

Xcovery Holdings, Inc.

Wolf, Greenfield & Sacks, P.C.

Open